Wall Street Zen Downgrades SAB Biotherapeutics and SURO Capital to Sell

The dual downgrade of SAB Biotherapeutics (SABS) and SURO Capital (SSSS) by Wall Street Zen on March 17, 2026, marks a significant shift in sentiment for two distinct but high-risk corners of the market: clinical-stage biotechnology and venture-backed private equity. While the firms operate in different sectors, the synchronized 'Sell' ratings suggest a broader tightening of risk tolerance among analysts as the first quarter of 2026 nears its end. This move by Wall Street Zen, a platform known for its data-driven equity analysis, likely reflects underlying concerns about cash runways and the realization of asset values in a volatile macroeconomic climate.

SAB Biotherapeutics, a company specializing in the development of human polyclonal antibodies through its proprietary DiversitAb platform, has long been a 'high-conviction' play for investors betting on the next generation of immunotherapy. However, the downgrade to 'Sell' likely stems from the persistent challenges facing mid-cap biotech firms in 2026: high operational cash burn and the 'binary risk' associated with late-stage clinical trial outcomes. In an environment where capital is no longer cheap and investors are prioritizing near-term profitability, companies without a commercialized product face intense scrutiny. For SABS, the market is looking for more than just scientific promise; it requires a clear path to revenue that may currently be obscured by regulatory hurdles or developmental delays in its lead programs.

“

This move by Wall Street Zen, a platform known for its data-driven equity analysis, likely reflects underlying concerns about cash runways and the realization of asset values in a volatile macroeconomic climate.

On the other hand, SURO Capital represents a different set of risks. As a Business Development Company (BDC) that provides public investors access to late-stage, venture-backed private companies—often in the AI, fintech, and space-tech sectors—SURO's performance is a direct reflection of the IPO market's health. A 'Sell' rating here suggests that Wall Street Zen anticipates a continued 'valuation gap' between private marks and public reality. If the IPO window remains narrow or if private companies are forced into 'down rounds' to secure funding, SURO’s Net Asset Value (NAV) could face significant downward pressure. This downgrade serves as a warning shot for the broader BDC sector, which has enjoyed a period of popularity due to high dividend yields but now faces questions about the quality of underlying private assets.